# Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

> **NCT02176213** · PHASE2 · COMPLETED · sponsor: **Ajai Chari** · enrollment: 35 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02176213
- **Lead sponsor:** Ajai Chari
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2019-05-07
- **Final completion:** 2019-05-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176213, "Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02176213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*